Darsana Capital Partners LP Invests $29.07 Million in Sotera Health (NASDAQ:SHC)

Darsana Capital Partners LP acquired a new position in shares of Sotera Health (NASDAQ:SHC) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,449,364 shares of the company’s stock, valued at approximately $29,074,000. Sotera Health accounts for approximately 0.8% of Darsana Capital Partners LP’s portfolio, making the stock its 13th largest position. Darsana Capital Partners LP owned approximately 0.87% of Sotera Health as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of SHC. CWM LLC boosted its position in Sotera Health by 86.1% during the second quarter. CWM LLC now owns 2,146 shares of the company’s stock worth $25,000 after purchasing an additional 993 shares in the last quarter. Point72 DIFC Ltd raised its position in Sotera Health by 556.6% during the second quarter. Point72 DIFC Ltd now owns 6,540 shares of the company’s stock worth $78,000 after acquiring an additional 5,544 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Sotera Health by 728.0% in the second quarter. Acadian Asset Management LLC now owns 9,381 shares of the company’s stock valued at $111,000 after purchasing an additional 8,248 shares during the last quarter. Sandia Investment Management LP purchased a new position in shares of Sotera Health during the 1st quarter worth approximately $120,000. Finally, Securian Asset Management Inc. increased its stake in shares of Sotera Health by 23.0% during the 1st quarter. Securian Asset Management Inc. now owns 10,178 shares of the company’s stock worth $122,000 after purchasing an additional 1,900 shares in the last quarter. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Insiders Place Their Bets

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of Sotera Health stock in a transaction on Friday, September 6th. The shares were sold at an average price of $15.03, for a total transaction of $150,300,000.00. Following the sale, the director now owns 49,215,301 shares of the company’s stock, valued at approximately $739,705,974.03. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 55.12% of the stock is owned by company insiders.

Sotera Health Stock Performance

Sotera Health stock opened at $16.59 on Thursday. The company has a debt-to-equity ratio of 5.46, a current ratio of 2.93 and a quick ratio of 2.59. Sotera Health has a 12 month low of $10.71 and a 12 month high of $17.44. The company has a market cap of $4.70 billion, a price-to-earnings ratio of 87.22 and a beta of 2.07. The stock’s 50-day moving average is $15.04 and its 200-day moving average is $12.88.

Sotera Health (NASDAQ:SHC) last posted its earnings results on Monday, August 5th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.04. Sotera Health had a net margin of 3.65% and a return on equity of 47.26%. The business had revenue of $277.00 million for the quarter, compared to analyst estimates of $266.45 million. During the same quarter in the previous year, the business posted $0.19 EPS. The business’s quarterly revenue was up 8.6% on a year-over-year basis. Equities analysts anticipate that Sotera Health will post 0.64 earnings per share for the current year.

Analyst Ratings Changes

SHC has been the subject of a number of recent research reports. Barclays lifted their price objective on Sotera Health from $14.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $17.00 target price on shares of Sotera Health in a research note on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $15.70.

Sotera Health Company Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.